Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,541 to 1,560 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Parenteral Nutrition vs Enteral Nutrition: Post-procedural Sepsis | 129 of 2,912 108 of 2,912 | 0.7 points -0.3 to 1.7 | 5,824 | NCT02512224 Comparison of Outcomes Between Parenteral and Enteral Nutrition |
| Parenteral Nutrition vs Enteral Nutrition: Mortality Calculated From Outcome Section From DPC Database at 30 Days | 114 of 2,912 89 of 2,912 | 0.9 points -0.1 to 1.8 | 5,824 | NCT02512224 Comparison of Outcomes Between Parenteral and Enteral Nutrition |
| Parenteral Nutrition vs Enteral Nutrition: Mortality Calculated From Outcome Section From DPC Database at 14 Days | 114 of 2,912 89 of 2,912 | 0.9 points -0.1 to 1.8 | 5,824 | NCT02512224 Comparison of Outcomes Between Parenteral and Enteral Nutrition |
| Canagliflozin (Experimental) vs Placebo (Placebo): deaths from any cause | 68 of 2,904 71 of 2,903 | -0.1 points -0.9 to 0.7 | 5,807 | NCT01989754 A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus |
| Canagliflozin (Experimental) vs Placebo (Placebo): serious adverse events | 714 of 2,904 775 of 2,903 | -2.1 points -4.4 to 0.1 | 5,807 | NCT01989754 A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus |
| Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Decision to Prescribe Antibiotics for Adult Pharyngitis | 1,464 of 2,032 2,492 of 3,764 | 5.8 points 3.4 to 8.3 | 5,796 | NCT06027593 Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions |
| Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Use for Adults With Pharyngitis | 1,458 of 2,032 2,477 of 3,764 | 5.9 points 3.4 to 8.4 | 5,796 | NCT06027593 Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions |
| Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: 30-day Pharyngitis Outpatient Revisits (Emergency Department, Urgent Care, or Primary Care) in Adults | 291 of 2,032 578 of 3,764 | -1.0 points -2.9 to 0.9 | 5,796 | NCT06027593 Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions |
| Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: 30-day Deep Neck Space Infection Admission | 0 of 2,032 1 of 3,764 | -0.0 points -0.2 to 0.2 | 5,796 | NCT06027593 Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions |
| Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) vs Arm 2: Main Cohort: Group 2: Placebo: Main Cohorts:Number of Participants With Serious Adverse Events (SAEs) | 203 of 2,891 196 of 2,891 | 0.2 points -1.1 to 1.6 | 5,782 | NCT03982199 A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older |
| PDE5 Inhibitors vs Endothelin Receptor Antagonists: deaths from any cause | 327 of 2,888 407 of 2,888 | -2.8 points -4.5 to -1.1 | 5,776 | NCT05039086 Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5 |
| Cervarix Group vs Aluminium Hydroxide Group: serious adverse events | 291 of 2,881 269 of 2,871 | 0.7 points -0.8 to 2.3 | 5,752 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| 30% Oxygen vs 80% Oxygen: Number of Participants With Superficial SSI (Surgical Site Infection) | 183 of 2,853 150 of 2,896 | 1.2 points 0.0 to 2.5 | 5,749 | NCT01777568 Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project |
| 30% Oxygen vs 80% Oxygen: deaths from any cause | 10 of 2,853 20 of 2,896 | -0.3 points -0.7 to 0.0 | 5,749 | NCT01777568 Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project |
| 30% Oxygen vs 80% Oxygen: Number of Participants With One or More Composite Complications | 314 of 2,853 314 of 2,896 | 0.2 points -1.5 to 1.8 | 5,749 | NCT01777568 Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project |
| 30% Oxygen vs 80% Oxygen: serious adverse events | 314 of 2,853 314 of 2,896 | 0.2 points -1.5 to 1.8 | 5,749 | NCT01777568 Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project |
| Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting New Onset of Autoimmune Disease (NOADs). | 24 of 2,877 24 of 2,870 | -0.0 points -0.5 to 0.5 | 5,747 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting Medically Significant Conditions (MAEs). | 1,170 of 2,877 1,140 of 2,870 | 0.9 points -1.6 to 3.5 | 5,747 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study. | 28 of 2,877 14 of 2,870 | 0.5 points 0.0 to 1.0 | 5,747 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
| Cervarix Group vs Aluminium Hydroxide Group: Number of Subjects Reporting New Onset of Chronic Disease (NOCDs). | 143 of 2,877 165 of 2,870 | -0.8 points -2.0 to 0.4 | 5,747 | NCT00294047 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=78
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02512224-774ba4de",
"title": "Parenteral Nutrition vs Enteral Nutrition: Post-procedural Sepsis",
"summary": "129 of 2912 against 108 of 2912; risk difference 0.7 points, 95% interval -0.3 to 1.7; NCT02512224, Comparison of Outcomes Between Parenteral and Enteral Nutrition",
"record": "/library/comparisons/NCT02512224-774ba4de",
"nct_id": "NCT02512224",
"kind": "outcome",
"participants": 5824,
"risk_difference": {
"value": 0.007211538461538464,
"lower": -0.0029714610473166817,
"upper": 0.017452996996872285
},
"group_1": "129 of 2,912",
"group_2": "108 of 2,912",
"difference": "0.7 points",
"interval": "-0.3 to 1.7",
"trial_title": "Comparison of Outcomes Between Parenteral and Enteral Nutrition"
},
{
"id": "NCT02512224-931432c4",
"title": "Parenteral Nutrition vs Enteral Nutrition: Mortality Calculated From Outcome Section From DPC Database at 30 Days",
"summary": "114 of 2912 against 89 of 2912; risk difference 0.9 points, 95% interval -0.1 to 1.8; NCT02512224, Comparison of Outcomes Between Parenteral and Enteral Nutrition",
"record": "/library/comparisons/NCT02512224-931432c4",
"nct_id": "NCT02512224",
"kind": "outcome",
"participants": 5824,
"risk_difference": {
"value": 0.008585164835164836,
"lower": -0.0008636105443717516,
"upper": 0.018119721196091877
},
"group_1": "114 of 2,912",
"group_2": "89 of 2,912",
"difference": "0.9 points",
"interval": "-0.1 to 1.8",
"trial_title": "Comparison of Outcomes Between Parenteral and Enteral Nutrition"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=79",
"request_id": "_Kn-q399jMaBB3VJ"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant